In vivo treatment of mice bearing EGFRvIII-expressing glioblastoma with the PAK4 inhibitor KPT9274 led to sensitization of the tumors to the cellular immunotherapy with enhanced tumor clearance and survival compared to CAR T cells or KPT9274 treatment alone [107]. The gene discussed is PAK4; the disease is neoplasm.